Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Dissecting publication timelines: Insights from high-impact oncology journals.
Aljafari, Abdulmalek , Khairi, Ahmad, Aljafari, Abdulmoiz , Hebishy, Ahmed, Batoo, Sameer, Mohammad, Abdulkader

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 9037-9037

10.1200/jco.2025.43.16_suppl.9037 Get It

9037 Background: Efficient dissemination of research findings is critical in oncology, where timely access to new knowledge impacts clinical care and outcomes. This study analyzes publication timelines of high-impact oncology journals to identify patterns and determinants, including research categories and study designs. Methods: This is a retrospective observational study. Journals with the highest impact factors and available publication timeline data were included: Journal of Clinical Oncology, Molecular Cancer, Clinical Cancer Research, and Cancer Discovery. All articles published in 2023 were analyzed for submission-to-acceptance, acceptance-to-publication, and total publication times. Data were processed using SPSS, and statistical comparisons were made with the Kruskal-Wallis test (significance: p<0.05). Results: A total of 875 articles were analyzed. The overall median total publication time (TT) was 7.1 months (IQR: 5.7–8.9), with submission-to-acceptance (AT) and acceptance-to-publication (PT) medians of 4.8 months (IQR: 3.5–6.3) and 2.2 months (IQR: 1.6–2.6), respectively. Among journals, Molecular Cancer exhibited the shortest TT (median: 4.7 months; IQR: 3.1–6.6), while Cancer Discovery had the longest TT (median: 8.8 months; IQR: 6.8–10.6). Similarly, Molecular Cancer achieved the fastest AT (median: 3.9 months; IQR: 2.2–5.4) and PT (median: 0.6 months; IQR: 0.4–1.1). Conversely, Cancer Discovery recorded the slowest AT (median: 6.0 months; IQR: 4.5–7.8) and PT (median: 2.8 months; IQR: 2.4–3.2). In terms of research categories, blood cancer articles accounted for the largest proportion of publications (14.4%), followed by gastrointestinal cancer (13.9%). Articles in genitourinary (median TT: 6.4 months; IQR: 5.5–8.8) and cardiac cancer (median TT: 6.5 months; IQR: 5.9–6.9) categories had the shortest TT, while endocrine (median TT: 7.9 months; IQR: 5.6–10.9) and immunotherapy (median TT: 9.1 months; IQR: 6.8–10.5) categories exhibited the longest TT (p<0.05). Clinical trials were the most common study design (37.6%), followed by cross-sectional studies (19.5%). Systematic reviews had the shortest TT (median: 2.4 months; IQR: 1.9–9.2), while proof-of-concept studies required the longest TT (median: 9.5 months; IQR: 8.7–10.7) (p<0.05). Systematic reviews and database studies also had the shortest PT (median: 1.5 months), whereas proof-of-concept studies had the longest PT (median: 2.8 months; p<0.001). Conclusions: Publication timelines in oncology journals vary significantly by journal, research category, and study design. Molecular Cancer demonstrates the fastest publication processes, while Cancer Discovery exhibits the slowest. Genitourinary and dermatologic oncology categories, as well as systematic reviews, achieve the most expedited timelines, emphasizing the need to consider category and study design in publication planning.
Applying learning science principles (LSP) through a simulation session (SIM) for oncology trainees (OT) about fertility preservation (FP) in patients (pts) with cancer and treatment (tx) of pregnant pts (TPP) with cancer.
Pai, Tanmayi , Correia, Guilherme Sacchi de Camargo, Wysokinska, Ewa , Abdel-Razeq, Nayef Hikmat, Adeoye, Oluwatayo , Aldapt, Mahmood B, Kamatham, Saivaishnavi , Tawfiq, Reema, Wolf, Emily, Rao, Rohit , Tan, Winston, Ventro, Sandra, Abdelhakeem, Ahmed , Baidoun, Firas , Elantably, Dina , Gupta, Kush , Mosalem, Osama , Wiest, Nathaniel E. , Iqbal, Madiha , Tan, Winston, Manochakian, Rami

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 9029-9029

10.1200/jco.2025.43.16_suppl.9029 Get It

9029 Background: Addressing guideline concordant FP and TPP with cancer is challenging, especially for OT. SIM, a well-known education tool, has not been traditionally used to teach these topics. As part of the hematology/oncology fellowship curriculum, we designed a SIM applying LSP to bridge this educational gap. Methods: Applying LSP of contrasting cases, elaboration, feedback, generation and just-in-time telling, chief OTs and faculty designed a SIM with 3 clinical scenarios (CS) and 3 standardized pts (SP): FP for a female pt hospitalized for acute lymphoblastic leukemia tx, FP for a male pt in clinic for germ cell tumor tx, and breast cancer tx for a pregnant pt in 2 nd trimester. OT received written educational materials (WEM) and attended a lecture 1 week and 1 day pre SIM, respectively. OT were split into 2 groups; 1 started in the FP CS and 1 in the TPP CS, and then they switched. To reduce cognitive overload, each OT participated in 1 of 2 FP CS: half in the female FP CS and half in the male. Faculty and chiefs led debriefing sessions after all CS. The FP debrief ended with a special “learner as a teacher” part, where OT who attended the female CS taught those from the male CS about their topic and vice versa. The SIM concluded with "take-home" points. Pre (after having WEM) and post SIM anonymous surveys and verbal feedback assessed OT comfort, perceptions, and knowledge. Results: A 3 hour SIM with 14 OT and 5 faculty was completed successfully. SIM ended with all OT verbally sharing a learning point and positive feedback. All OT filled pre and post SIM surveys. Pre SIM, 17% reported having prior FP education, and 42% had prior TPP education. However, only 8% and 25% felt adequately prepared for FP and TPP discussions, respectively. Post SIM survey showed major improvement in comfort and knowledge about FP and TPP (see table 1). 75% of OT favored a combination of SIM and learning by teaching over other SIM formats. 83% supported having a TPP lecture before SIM. 100% reported satisfaction with FP and TPP SIM’s quality and wanted similar activities in the future. 92% were satisfied with the learner as a teacher tool. 100% felt education about FP and TPP with cancer should be part of fellowship training. Moral/cultural concerns were discussed as possible challenges in FP education. Conclusions: The application of LSP through SIM significantly increased OTs’ comfort discussing FP and TPP with cancer, and objectively enhanced their knowledge on these topics compared to after reading WEM. The SIM was largely perceived as a successful activity to educate about challenging topics and should become part of fellowship curriculum. Pre SIM % Post SIM % Comfortable addressing FP 17 92 Comfortable addressing TPP 8 100 Correct answers about female FP 63 83 Correct answers about male FP 67 94 Correct answers about TPP with cancer 68 98
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
Cervera, Victor, Block, Matthew S. , Mäenpää, Johanna , Arias, Victor , Heijden, Mirte van der , Haybout, Lyna , Ramadan, Susan, Sorsa, Suvi , Santos, João M. , Clubb, James H.A. , Pakola, Santeri A. , Quixabeira, Dafne C.A. , Kudling, Tatiana Viktorovna , Jirovec, Elise , Alanko, Tuomo , Adamo, Daniel A. , Sormunen, Jorma , Chisamore, Michael Jon , Hemminki, Akseli

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 5555-5555

10.1200/jco.2025.43.16_suppl.5555 Get It

5555 Background: Platinum-resistant/refractory ovarian cancer presents a significant therapeutic challenge and despite several attempts, immunotherapies have not delivered satisfactory results to be approved. Identifying biomarkers of response to novel therapies is crucial for personalizing treatments and improving patient outcomes, especially since certain patients do experience long term benefit after the treatment with pembrolizumab and igrelimogene litadenorepvec (TILT-123; an oncolytic adenovirus coding for TNF and IL-2). Methods: Tumor biopsies (n=62), ascites (n=8) and blood (n=234) were collected from 15 patients treated in the PROTA trial (Phase I, NCT05271318). These patients received pembrolizumab intravenously plus igrelimogene litadenorepvec intravenously, followed by local administration intratumorally or intraperitoneally. Sampling took place prior to therapy, during therapy and after it. Tumor proteome (IHC, mIF) and transcriptome was analyzed to assess immune changes and virus presence. Ascites and blood samples were assayed to measure cell counts, phenotypes, cytokine and protein counts, as well as for the presence of antiviral neutralizing antibodies (NAbs). Biological parameters were correlated with overall survival (OS), RECIST 1.1 evaluations and tumor size changes. For analysis of OS, logrank test was used. For group comparisons two-tailed Mann-Whitney U-test was used. Pearson or Spearman tests were used for correlations. Results: Patients experiencing a drop in circulating lymphocytes 8-24 hours after treatment were more likely to experience longer OS (p=0.044). Additionally, patients with a higher lymphocyte count at baseline experienced similar OS benefit (p=0.018) plus a positive correlation with disease control (p=0.023). Most patients (11/15) showed antiviral immunity at baseline but eventually all patients developed neutralizing activity, and the same was observed in ascites. The presence of NAbs at baseline as well as development of highest titers were positively correlated with longer OS (p=0.004) and disease control (p=0.003). Conclusions: Igrelimogene litadenorepvec and pembrolizumab are therapies designed to attract, activate and/or protect lymphocyte-mediated antitumor activity. These findings suggest that having a fit immune system able to mobilize effector immune cells as well as responding to immunostimulant agents increases therapeutic success. As a disease with few therapeutic options, ovarian cancer patients often receive multiple lines of chemotherapy that might decrease the efficacy of immediate immunotherapies. The potential use of these biomarkers will be studied in larger studies to validate their utility in guiding the use of immunotherapy in this challenging patient population. Clinical trial information: NCT05271318 .
A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512).
Lee, Elizabeth Katherine, Hendrickson, Andrea E. Wahner , Krasner, Carolyn, Stover, Elizabeth H. , Porter, Rebecca L. , Matulonis, Ursula A. , Xiong, Niya , Sawyer, Hannah, Tayob, Nabihah , Lee, Elizabeth Katherine , Zhou, Yinglu , Fleming, Gini F. , Konstantinopoulos, Panagiotis A. , Horowitz, Neil S. , Wright, Alexi A. , Sawyer, Hannah , Liu, Joyce F.

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 5515-5515

10.1200/jco.2025.43.16_suppl.5515 Get It

5515 Background: Clear cell ovarian carcinoma (CCOC) is a chemoresistant subtype of ovarian cancer. Immune checkpoint inhibitors have been reported to have clinical activity in CCOC. Additionally, CCOC harbors molecular alterations suggesting a role for anti-angiogenic agents. We therefore conducted a single-arm two-stage phase 2 trial to investigate the clinical activity of the combination of the PD-1 inhibitor pembrolizumab with the anti-angiogenic tyrosine kinase inhibitor lenvatinib in patients (pts) with CCOC. Methods: Pts with CCOC and measurable disease received pembrolizumab 200 mg IV every 3 weeks and lenvatinib 20 mg daily. Pts could have received an unlimited number of prior therapies; prior bevacizumab and immune checkpoint inhibitors were allowed, but prior lenvatinib was exclusionary. Malignant bowel involvement was not allowed. Co-primary endpoints were objective response rate (H 0 5%; H a 25%) and rate of PFS at 6 months (mo) per RECIST v1.1 (H 0 10%; H a 30%), restricting the probabilities of type I and type II errors to 10% and 10%, respectively. Two pts with objective responses or 3 pts progression-free and alive at 6 mos were needed to proceed from stage 1 (n=18) to stage 2 (n=13); 5 pts with objective responses or 6 pts progression-free and alive at 6 mos were needed to declare the combination worthy of further study. Results: Data cut-off occurred 22-Oct-2024. Of 30 enrolled pts, 83.3% were white; the mean age among all pts was 54.1 years. 30% of pts (9/30) experienced a confirmed response (2 CR, 7 PR); an additional 3 pts (10%) experienced unconfirmed PRs and 4 pts (13.3%) had SD ≥6 mo. As of data cut-off, 3 pts (10%) had not yet reached their first radiographic assessments, and 17 pts were still receiving study therapy. With a median of 9.72 mo of follow up, 16 pts were alive and progression-free at 6 months. The estimated 6-month PFS was 75.96% (95% CI 53.82-88.51%). Median PFS was 10.9 mo. The estimated 12-month PFS was 48.86% (95% CI 23.67-70.04%). The most common any-grade TRAEs were hypertension (71%), hypothyroidism (66%), and fatigue (60%). There were no unanticipated TRAEs. Conclusions: The combination of pembrolizumab/lenvatinib demonstrates encouraging evidence of clinical activity in CCOC, with 9 pts experiencing a confirmed response and 16 pts alive and progression-free at 6 months. As both co-primary endpoints of the study were met, enrollment closed with 30 pts. Updated data for all pts will be reported. There were no new safety signals. Clinical trial information: NCT05296512 .
Interim safety and efficacy data of [ 212 Pb]VMT01 in MC1R expressing melanoma.
Block, Matthew S. , Mehr, Samuel H., Baratto, Lucia , Tomash, Haley, Yang, Wenjing , Puhlmann, Markus , Morris, Zachary Scott , Wahl, Richard L. , Marsh, Ian R. , O’Keefe, Stephen J. , Menda, Yusuf

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3099-3099

10.1200/jco.2025.43.16_suppl.3099 Get It

3099 Background: Immune checkpoint inhibitors (ICI) are effective in melanoma, but many patients experience progression on or after approved ICI +/- MAPK inhibitor therapy. Melanocortin-1 receptor (MC1R) is a novel target for radiopharmaceutical therapy (RPT) and is highly expressed on melanoma tumor cells. VMT01 is an MC1R-targeted RPT that can be radiolabeled with either 203 Pb (patient selection and dosimetry assessments) or 212 Pb (alpha particle therapy). Here, we present data on the first in-human evaluation of [ 203 Pb/ 212 Pb]VMT01 in patients with metastatic melanoma. FDA granted Fast Track Designation to the product on the bases of preclinical experiments combining [ 212 Pb]VMT01 with immunotherapy. Methods: This is a first-in-human dose-finding study to determine the safety, pharmacokinetics, dosimetry and preliminary efficacy of [ 212 Pb]VMT01 in subjects with MC1R-positive metastatic melanoma who progressed on at least 1 approved first-line therapy (NCT05655312). Phase 1 of the trial includes escalating dose cohorts. The first two cohorts incorporate dosimetry evaluations (reported separately) with the imaging surrogate [ 203 Pb]VMT01 prior to receiving up to 3 treatment cycles of [ 212 Pb]VMT01 therapy (injected activity of 111 MBq (3 mCi) or 185 MBq (5 mCi) for Cohort 1 and 2, respectively). Participants are evaluated for any DLT for the first 6 weeks after cycle one. Efficacy is assessed by RECIST 1.1 criteria by the investigator. Following the start of the study the anticipated combination arm with nivolumab was opened as an amendment. Results: Cohort 1 (DCO 04Sep24) was completed with 3 enrolled participants who received 3 treatment cycles without any DLTs or SAEs. Cohort 1 participants showed prolonged stabilization of disease from start of treatment (mean: 11.1 months); one participant developed a confirmed objective response (PR) after completion of all three [ 212 Pb]VMT01 administrations and is still on trial after 13.1 months from start of treatment. Cohort 2 has completed with 7 enrolled participants. No DLTs or related SAEs have been observed. All participants in this Cohort progressed after either the first cycle (3 participants) or the second cycle (4 participants).Based on these preliminary results showing anti-tumor effect at the lower dose, additional cohorts for both monotherapy and in combination with nivolumab were introduced at a de-escalated dose of 55.5 MBq (1.5 mCi). Both cohorts are now open for enrollment. Updated safety and efficacy data will be analyzed and presented at ASCO. Conclusions: At 111 MBq and 185 MBq activity levels, [ 212 Pb]VMT01 was safe and well-tolerated. An objective response and prolonged stabilization of disease were observed at the 111 MBq activity level while no effect was seen at 185 MBq. The study will continue to explore potentially immunostimulating lower doses of administered activity of [ 212 Pb]VMT01 either as a monotherapy or in combination with nivolumab. Clinical trial information: NCT05655312 .
Phase 2 multicenter clinical trial to evaluate the safety and efficacy of abenacianine for injection (VGT-309), a tumor-targeted, intraoperative molecular imaging agent, for patients undergoing surgery for cancer in the lung.
Singhal, Sunil, Kim, Jae Y. , Reisenauer, Janani , Rice, David C. , Singhal, Sunil Kumar , Herrera, Luis J., Wright, Gavin Michael

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3069-3069

10.1200/jco.2025.43.16_suppl.3069 Get It

3069 Background: Molecular targeted agents have revolutionized cancer diagnosis and treatment. Intraoperative molecular imaging (IMI) is a novel technique that entails performing real-time, in vivo optical imaging during surgery to ensure cancer clearance. A multicenter clinical trial was conducted using abenacianine, a cathepsin targeted near-infrared (NIR) IMI agent to visualize pulmonary nodules during surgery. The primary objective was to assess the efficacy of abenacianine in localizing pulmonary lesions, evaluating surgical margin, and identifying unsuspected disease. Methods: Participants scheduled to undergo surgery for known or suspected cancer in the lung received abenacianine (0.32 mg/kg intravenous) preoperatively 12 to 36 hours before surgery. During a standard-of-care surgery, the lung underwent IMI and additional disease not identified by conventional methods were identified and analyzed. Efficacy was measured by frequency of clinically significant events (CSEs) defined as localization of lesions not found by standard surgical techniques, identification of additional cancers, identification of positive surgical margins confirmed by histology, and detection of cancerous lymph nodes. Results: 89 participants were included in the study. The mean age was 67 years and 57 (64%) were female. Of 89 participants administered abenacianine who underwent standard of care surgical resection for known or suspected cancer in the lung, 40 (45%) had at least one CSE. Abenacianine with NIR imaging identified lesions that were not found by standard surgical methods in 34 (38%) participants, synchronous and occult cancers that were not found by pre-operative imaging in 2 (2%), margins within 10 mm of the closest staple line in 8 (9%), and lymph nodes determined to be cancerous in 1 (1%) participant. Tumors visualized by IMI with abenacianine included non-small cell lung cancers (adenocarcinoma, squamous cell carcinoma, neuroendocrine tumor) and cancers that metastasized to the lung (breast, colorectal, prostate, thymoma, renal cell, sarcoma). Abenacianine was safe and well tolerated in this study; there were no drug-related serious adverse events. Conclusions: This Phase 2 multicenter study demonstrated that using IMI with abenacianine during standard-of-care lung cancer surgery markedly improved clinical outcomes. Abenacianine localized tumors intraoperatively, identified synchronous and occult lesions, helped assess negative margin status, and identified cancerous lymph nodes enabling a more complete oncologic resection. Clinical trial information: NCT06145048 .
Perceptions of Vietnamese women regarding HPV self-collection: A cross-sectional analysis.
Dinh, Tri, Islam, Nadia, Dinh, Tri

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e17530 Get It

e17530 Background: Cervical cancer remains a significant public health challenge, especially in low-resource settings such as Vietnam. HPV self-collection offers a promising avenue for improving screening uptake, yet its acceptance depends on addressing knowledge gaps and sociocultural barriers. This study aims to explore the perceptions of Vietnamese women in regard to HPV and HPV self-collection, emphasizing strategies for health promotion and disease prevention. The aims of this study were to summarize responses to a 51-item survey regarding perceptions of HPV self-collection in Vietnamese women between 30 and 65 years old, as well as to compare survey responses according to age, religion, education level, marital status, and frequency of doctor visits in the past year. Methods: A survey of 538 women aged 30–65 assessed cervical cancer knowledge, attitudes toward HPV self-collection, cost concerns, and communication preferences. Associations between demographic factors and perceptions were analyzed using Wilcoxon rank sum, Kruskal-Wallis, and Fisher’s exact tests (p < 0.05). Results: While 84.4% of respondents were aware of cervical cancer, only 59.0% had knowledge of HPV, and 41.3% were familiar with self-collection. Most women (82.5%) recognized the importance of cervical cancer prevention; however, only 45.5% viewed self-collection as equally effective as doctor-administered testing. For negative self-collection recorded results, 64.3% felt reassured, yet 81.1% preferred secondary confirmation by a doctor (p<0.01). Cost concerns were notable, with 56.5% willing to pay 400,000 VND but fewer accepting higher costs. Education significantly influenced responses, with higher-educated women demonstrating greater awareness and confidence in self-collection (p < 0.001) . Importantly, participants identified doctors and healthcare professionals as trusted sources of information, when compared to other sources of information such as television and government officials, underscoring the role of health promotion campaigns. Conclusions: Effective health promotion strategies are critical to increasing HPV self-collection uptake in Vietnam. Public health campaigns should prioritize education to address misconceptions, emphasize the efficacy of self-collection, and reduce stigma. Programs that leverage trusted communication channels, such as healthcare providers, can foster trust and improve participation. Efforts to ensure affordability and accessibility are essential to achieving equitable and widespread cervical cancer prevention.
Cervical cancer treatment patterns & outcomes in sub-Saharan Africa: Findings from a multi-institutional cancer dataset.
Mina, Syeda A. , Ochieng, Primus, Addison, Eric, Manirakiza, Achille , Kemper, Katherine E. , Konney, Thomas O., Fekadu, Adugna, Mwango, Gladys , Mongare, Ben Roger, Dibaba, Yonas, Bogan, Aaron, Truman, Matt, Merrell, Kenneth W. , Osei‐Bonsu, Ernest , Falade, Ayo , Dibaba, Yonas, Dodoo, Christopher , Woldetsadik, Edom Seife

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e17511 Get It

e17511 Background: Cervical cancer is a significant public health concern in Sub-Saharan Africa (SSA), where it remains the leading cause of cancer-related mortality among women. SSA has the highest global incidence and mortality rates, with an estimated 110,300 new cases and 76,700 deaths in 2020. Despite this burden, data on patient characteristics and treatment outcomes remain limited. This study aims to address these gaps by analyzing current treatment patterns and outcomes for cervical cancer in SSA. Methods: A cancer dataset was established at 4 major teaching hospitals in Ghana, Kenya, Ethiopia, and Rwanda to capture data on patient demographics, disease characteristics, and treatment modalities. The dataset encompasses all cancer patients seen between 2016-2023, with over 9,000 cases collected to date. The primary objective of the dataset was to assess impact of COVID-19 pandemic on cancer care in SSA. This study conducted a retrospective analysis of cervical cancer cases within the dataset utilizing descriptive metrics. Results: A total of 2,326 patients were analyzed, with a median age at diagnosis of 56 y (48–65) and 53% having health insurance. The majority had squamous cell carcinoma (87%) and presented with locally advanced disease (FIGO stages IIB–IVA, 88%). Treatment primarily consisted of concurrent chemoradiotherapy (CRT, 34%) or radiotherapy (RT) alone (30%), while smaller proportions received chemotherapy (CT) alone (1.2%) or surgery (1.3%). A total of 33% of patients received no cancer therapy. Among 1,524 patients treated with RT, 1,180 received external beam RT with a median dose of 46 Gy in 23 fractions, using 2D planning in 60% and 3D planning in 40% of cases. Additionally, 25 patients underwent brachytherapy, with 58% receiving low-dose-rate and 42% high-dose-rate treatments. Of 1,011 patients treated with CT, 85% (n=844) completed the intended course, with a median of 4 cycles, primarily delivered concurrently with RT (95%). Only a few received CT as adjuvant (4.8%), neoadjuvant (1.6%), or palliative (3.4%) therapy. Platinum-based regimens were most common, with 43% receiving platinum monotherapy and 5% receiving platinum-taxane combinations. By the end of treatment, 27% (n=633) achieved disease-free status. After a median follow-up of 47 months (range,37–55), 42% were alive, 7% had died, and 53% were lost to follow-up with unknown vital status. Conclusions: This study reveals significant challenges in management and follow-up of cervical cancer in SSA. Most patients were diagnosed at advanced stages, with 32% receiving no treatment and 53% of treated patients lost to follow-up. These findings highlight barriers to early diagnosis, treatment access, and continuity of care. Addressing these issues requires expanding early diagnostic services, increasing vaccination coverage, strengthening healthcare infrastructure, and improving patient retention.
Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction.
Ruzgar, Nensi M. , Shafer, Amanda M., Schuetze, Scott M. , Klega, Kelly S. , Ricker, Cora A. , Tanhaemami, Mohammad , Reinke, Denise K. , Siontis, Brittany L. , Crompton, Brian D.

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3046-3046

10.1200/jco.2025.43.16_suppl.3046 Get It

3046 Background: Prior work has shown that detection of circulating tumor DNA (ctDNA) at time of diagnosis of leiomyosarcoma (LMS) is associated with lower likelihood of objective response and patients with detectable ctDNA after two cycles of chemotherapy have worse survival. However, because ctDNA exists at much lower concentrations in plasma compared to cell-free DNA of non-tumor origin, the sensitivity of these prognostic measures to tumor signals remains unclear. With increasing evidence of ctDNA fragments being shorter than the background non-tumor cell-free DNA, we sought to test whether restricting our analysis to smaller fragment sizes would improve detection of ctDNA in LMS. Methods: Plasma was serially collected from patients with LMS undergoing chemotherapy. Cell-free DNA extracted from these samples was profiled by ultra-low-passage whole-genome sequencing (ULPWGS). Copy number alterations were identified and used to detect ctDNA using the ichorCNA algorithm before and after restricting the dataset to fragments of 90-150bp (short). We compared detectability of ctDNA via ichorCNA between analyses using all sequencing data and those using data restricted to short fragments. Results: From 28 patients, 126 plasma samples were profiled. The median fragment length of cell-free DNA was 240bp (IQR 142-349) for patients with LMS, compared to 307bp (IQR 171-465, p < 0.001) in samples collected from healthy controls. Short fragments made up 19.48% of LMS libraries at diagnosis when ctDNA levels were highest, 15.27% of all LMS samples, and 12.96% of libraries from healthy controls. While ctDNA was detectable by ULPWGS in 17% of all samples, detection increased to 40% when analyzed using only short cell-free DNA fragments (p < 0.0001). The proportion of diagnostic samples with detectable ctDNA was nominally higher when analyzed by short fragments (39% vs. 64% with 90-150bp size restriction, p = 0.1078, n = 28) and was significantly higher in samples collected after two cycles of chemotherapy (5% vs. 40% with 90-150bp size restriction, p = 0.0197, n = 20). Increases in ctDNA detectability with fragment size restriction were also observed in each of localized and metastatic subgroups (metastatic: 16% without restriction, 38% with restriction, n = 97, p = 0.0012; localized: 17% vs. 45%, n = 39, p = 0.04). Conclusions: Our results demonstrate that detection of ctDNA is improved by analyzing short fragments of cell-free DNA in samples collected from patients with LMS. These findings represent a potential to increase the sensitivity of an affordable, low-coverage liquid biopsy assay and may enhance the prognostic value of ctDNA detection in these patients. Further study of the association between ctDNA detection and outcome is needed to fully validate the impact of fragment size restricted analysis of cell-free DNA samples in patients with LMS and is currently ongoing in a prospective study.
Trends and disparities in alcohol use and liver cell carcinoma–related mortality in the US: A 24-year retrospective study.
Aisha, Azka, Qadeer, Abdul , Khan, Saba , Khawar, Muneeb , Waqas, Muhammad , Komel, Aqsa, Khadim, Shaista , Naseer, Faisal, Asif, Hamza, Haider, Mobeen Z. , Kakakhel, Mian Zahid Jan , Laghari, Aamir, Haider, Ali , Kirchoff, Robert W.

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e16237 Get It

e16237 Background: Alcohol use (AU) and Liver cell carcinoma (LCC) are significant contributors to adult mortality worldwide. Examining trends and disparities in AU and LCC-related deaths is essential for understanding public health challenges and formulating targeted interventions. This study investigates national mortality patterns related to AU and LCC in the United States from 1999 to 2023, emphasizing demographic, geographic, and temporal disparities. Methods: This descriptive analysis used the CDC WONDER database (1999–2023) to identify AU-related deaths (ICD-10 codes E24.4, F10, G32.2, G62.1, G72.1, I42.6, K70, K85.2, K86.0, R78.0, T51, X65, Y15) and LCC (ICD-10 code C22.0) in adults aged 25 and older. Age-adjusted mortality rates (AAMRs) per 1,000,000 individuals were calculated, stratified by gender, race/ethnicity, census region, urban-rural classification, and state. Trends were analyzed using Joinpoint regression to compute annual percent changes (APCs) and 95% confidence intervals (CIs). Statistical significance was set at p < 0.05, and analyses adhered to STROBE guidelines. Results: From 1999 to 2023, a total of 21,007 deaths were attributed to LCC and AU (Men: 18,836 Women: 2,171). AAMRs showed a stable trend from 1999 to 2003 (APC: 0.0; 95% CI: -8.7 to 4.9) but increased significantly from 2003 to 2019 (APC: 6.1; 95% CI: 5.7 to 7.4), stabilizing from 2019 to 2023 (APC: -0.6; 95% CI: -3.2 to 1.3). Men's AAMRs decreased from 1999 to 2003 (APC: -1.1; 95% CI: -10.4 to 3.4), then rose sharply from 2003 to 2019 (APC: 6.1; 95% CI: 5.6 to 7.1). For women, AAMRs increased significantly, particularly between 2013 and 2017 (APC: 12.4; 95% CI: -9.5 to 25.1). Non-Hispanic Black and White populations experienced notable increases in AAMRs, while Hispanic people showed an initial decline followed by an increase post-2004 (APC: 4.7; 95% CI: 3.7 to 7.9). The West had the highest regional AAMR (5.3; 95% CI: 5.2 to 5.5), while the Northeast recorded the lowest (2.1; 95% CI: 2.0 to 2.2). New Mexico had the highest state AAMR (8.4; 95% CI: 7.4 to 9.4), and Mississippi the lowest (1.2; 95% CI: 0.9 to 1.5). AAMRs rose more sharply in non-metropolitan areas from 1999-2020 (APC: 6.6; 95% CI: 5.9 to 7.8) compared to metropolitan regions from 2004 to 2020 (APC: 5.4; 95% CI: 4.9 to 6.5). Conclusions: AU and LCC-related mortality rates have increased significantly since 2003, with distinct gender, racial, and geographic disparities. Men and rural populations faced higher mortality increases, with notable variations across states and regions. These findings underscore the need for focused public health efforts to mitigate these disparities and address the growing burden of LCC and AU-related mortality.